CHRSCoherus Oncology, Inc.

$219M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$45M-44.9% YoY

Gross Profit

$10M22.4% margin

Operating Income

-$80M-177.1% margin

Net Income

-$87M-190.8% margin

EPS (Diluted)

$-1.19

QoQ Revenue Growth

-24.5%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$38M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$551M

Total Liabilities

$648M

Stockholders' Equity

-$97M

Cash & Equivalents

$287M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$45M	$83M	-44.9%
Gross Profit	$10M	$61M	-83.4%
Operating Income	-$80M	-$33M	-145.4%
Net Income	-$87M	-$39M	-124.9%

CHRS Q3 2022 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena